1. Scrip
  2. >>Focus On Asia
  3. >>China

HUTCHMED Switches Clinical Strategy To Rely On Partnerships For Late-Stage Assets In US

 
• By Dexter Jie Yan

Having initiated China-only Phase III trials with three oncology and autoimmune drug candidates, HUTCHMED is looking for partnerships to take the molecules to the clinic in the US.

Asia strategy
HUTCHMED seeks partnerships to advance three molecules into the clinic outside of China. • Source: Shutterstock

Aiming to become profitable in 2025, HUTCHMED (China) Limited is likely to move away from running costly late-stage international clinical trials by itself, primarily in the US, and is instead seeking partnerships to advance three molecules into the clinic outside of China, company executives said during the group's R&D Day on 9 July.

Key Takeaways

  • HUTCHMED has initiated China-only Phase III or II/III clinical trials with three molecules, namely IDH 1 and IDH 2 dual inhibitor HMPL-306, Syk inhibitor sovleplenib and VEGFR/FGFR inhibitor surufatinib.

  • Data from these trials will determine the company's next steps for the late-stage clinical development of the molecules outside of China

The new approach is mostly pronounced in the clinical development of its isocitrate dehydrogenase (IDH) 1 and IDH 2 dual inhibitor HMPL-306

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

More from Focus On Asia